<DOC>
	<DOCNO>NCT02843347</DOCNO>
	<brief_summary>The STRIDE Biorepository optional substudy available participant `` Bone Marrow Transplantation v Standard Care Patients Severe Sickle Cell Disease ( BMT CTN 1503 ) ( STRIDE ) '' .</brief_summary>
	<brief_title>STRIDE Biorepository</brief_title>
	<detailed_description>A subset sit main study `` Bone Marrow Transplantation v Standard Care Patients Severe Sickle Cell Disease ( BMT CTN 1503 ) ( STRIDE ) '' ( NCT02766465 ) also participate biorepository portion study . The purpose biorepository examine DNA learn certain gene predict serious complication sickle cell disease . The STRIDE Biorepository optional substudy available individual enrol main study , participate site . Participants main study consent take part biorepository blood drawn Baseline Visit . This blood ship Emory University Atlanta Georgia store future research .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Age 15.00 40.99 year Severe sickle cell disease [ Hemoglobin SS ( Hb SS ) , Hemoglobin SC ( Hb SC ) Hemoglobin SBeta thalassemia ( Hb Sβ ) genotype ] least 1 follow manifestation : 1 . Clinically significant neurologic event ( stroke ) neurological deficit last &gt; 24 hour ; 2 . History two episode acute chest syndrome ( ACS ) 2year period precede enrollment despite institution supportive care measure ( i.e . asthma therapy ) ; 3 . Three pain crisis per year 2year period precede referral ( require intravenous pain management outpatient inpatient hospital set ) ; 4 . Administration regular red blood cell ( RBC ) transfusion therapy , define receive 8 transfusion per year ≥ 1 year prevent vasoocclusive clinical complication ( i.e . pain , stroke , acute chest syndrome ) ; 5 . An echocardiographic finding tricuspid valve regurgitant jet ( TRJ ) velocity ≥ 2.7 m/sec . Adequate physical function measure follow : 1 . Karnofsky/Lansky performance score &gt; equal 60 2 . Cardiac function : Left ventricular ejection fraction ( LVEF ) &gt; 40 % ; LV shorten fraction &gt; 26 % cardiac echocardiogram Multi Gated Acquisition ( MUGA ) Scan 3 . Pulmonary function : Pulse oximetry baseline O2 saturation ≥ 85 % diffusing capacity lung carbon monoxide ( DLCO ) &gt; 40 % ( correct hemoglobin ) 4 . Renal function : Serum creatinine ≤ 1.5 x upper limit normal age per local laboratory 24 hour urine creatinine clearance &gt; 70 mL/min ; GFR &gt; 70 mL/min/1.73 m2 radionuclide Glomerular Filtration Rate ( GFR ) 5 . Hepatic function : Serum conjugate ( direct ) bilirubin &lt; 2x upper limit normal age per local laboratory ; alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5 time upper limit normal per local laboratory . Patients hyperbilirubinemia consequence hyperhemolysis , experience sudden , profound change serum hemoglobin RBC transfusion exclude . Human Leukocyte Antigen ( HLA ) type prior referral ( consultation hematopoietic cell transplantation ( HCT ) physician ) . However , subject HLA type accompany documentation relative HLA type search unrelated donor registry perform subject consider eligible . Documentation review adjudicate Protocol Officer his/her designee . Uncontrolled bacterial , viral fungal infection 6 week enrollment . Seropositivity HIV . Previous HCT . Participation clinical trial patient receive investigational drug device must discontinue enrollment . A history substance abuse define version IV Diagnostic &amp; Statistical Manual Mental Disorders ( DSM IV ) . Demonstrated lack compliance prior medical care ( determine refer physician ) . Pregnant breast feeding female . Inability receive HCT due alloimmunization , define inability receive pack red blood cell ( pRBC ) transfusion therapy . Unwillingness use approve contraception method time biologic assignment discontinuation immunosuppressive medication assignment biologic assignment would donor arm . Additional Eligibility Criteria Transplant Biologic Assignment Donor Arm : Participants assign Donor Arm time biologic assignment subject additional transplant eligibility criterion specify . Additional , repeat clinical assessment prior transplant obtain accordance institutional policy standard care interest good clinical practice . Participants receive ≥8 pack red blood cell transfusion ≥1 year receive ≥20 pack red blood cell transfusion ( cumulative ) undergo liver magnetic resonance imaging ( MRI ) estimation hepatic iron content . Liver biopsy indicate hepatic iron content ≥7 mg Fe/gm liver dry weight . Histological examination must document absence cirrhosis , bridge fibrosis active hepatitis . The absence bridge fibrosis determine use histological grade stag scale describe Ishak colleague ( 1995 ) describe Manual Operating Procedures . Cerebral MRI/magnetic resonance angiogram ( MRA ) within 30 day prior initiation transplant conditioning . If clinical radiologic evidence recent neurologic event ( stroke transient ischemic attack ) subject defer least 6 month repeat cerebral MRI/MRA ensure stabilization neurologic event prior proceed transplantation . Absence donor specific HLA antibody Documentation participant 's willingness use approve contraception method discontinuation immunosuppressive medication . This document medical record correspond consent conference . The HLAmatched donor must medically fit donate willing donate bone marrow .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Biorepository</keyword>
	<keyword>Genetics</keyword>
</DOC>